Clinical trial data presented at the 2025 International Congress of Parkinson’s Disease and Movement Disorders showed that pimavanserin had positive efficacy in patients showing Parkinson Disease psychosis symptoms who were treated earlier.
Louie Pasculli
Advertisement
Louie Pasculli, Assistant Editor for NeurologyLive®, has been with the team since October 2025. Follow him on X @Louie_Pasculli or email him at [email protected]
Articles by Louie Pasculli
Advertisement
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Cladribine Tablets Show Ability to Improve or Stabilize Cognitive Function in Patients With Relapsing Multiple Sclerosis
2
Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers
3
Women Physicians Day 2026: Sex-Specific Clinical Considerations in Women With Epilepsy
4
Cladribine Maintains Efficacy, Safety Profile in Older Patients With Multiple Sclerosis
5